A pragmatic, non-randomized, non-inferiority study of evaluating efficacy and costs of Adalimumab treatment in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients: Ingebio Study

Trial Profile

A pragmatic, non-randomized, non-inferiority study of evaluating efficacy and costs of Adalimumab treatment in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) patients: Ingebio Study

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jul 2017 New trial record
    • 17 Jun 2017 Preliminary results presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top